Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Net profit rose in the second quarter compared to the same period of the previous year for German science and technology ...

The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and ...

XTRA:MRK 1 Year Share Price vs Fair Value Explore Merck KGaA's Fair Values from the Community and select yours ...

FRANKFURT, March 7 (Reuters) - Merck KGaA (MRCG.DE) forecast a return to modest operating earnings growth this year but only when adjusted for currency headwinds, citing a gradual recovery in ...

Merck KGaA is the world's largest still-operating pharma and healthcare company, with a 300+ year history. It has absolutely stellar fundamentals, and what risks do exist are well-covered by the ...

Narrow-moat Merck KGaA MRK delivered weak second-quarter results, and with these trends, management reduced its 2023 outlook. Mild tinkering with our near-term expectations does not materially ...

Germany’s Merck KGaA said Thursday that it expects a challenging 2023, with adjusted earnings forecast to be stable or decline slightly and a hit from foreign-exchange rates, as it reported a ...

Merck KGaA’s forecast caveat came as the company tallied 5.2 billion euros ($5.41 billion) in first-quarter revenue, signaling a 12.2% increase over the same period in 2021.

Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results The life-sciences and electronics company said its pre-items Ebitda rose to $6.55 billion By Helena Smolak Share ...